Last reviewed · How we verify

Vaxelis vaccine

Sanofi · Phase 3 active Biologic

Vaxelis vaccine is a Combination vaccine Biologic drug developed by Sanofi. It is currently in Phase 3 development for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilus influenzae type b, meningococcal disease (serogroup C), measles, mumps, rubella, and varicella in infants and children. Also known as: Vaxelis™, Vaxelis®.

Vaxelis is a combination vaccine that stimulates the immune system to produce antibodies and cellular immunity against multiple infectious diseases simultaneously.

Vaxelis is a combination vaccine that stimulates the immune system to produce antibodies and cellular immunity against multiple infectious diseases simultaneously. Used for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilus influenzae type b, meningococcal disease (serogroup C), measles, mumps, rubella, and varicella in infants and children.

At a glance

Generic nameVaxelis vaccine
Also known asVaxelis™, Vaxelis®
SponsorSanofi
Drug classCombination vaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

Vaxelis combines antigens from 11 different pathogens (diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilus influenzae type b, meningococcal serogroup C, measles, mumps, rubella, and varicella) in a single injection. It works by presenting these antigens to the immune system, triggering both humoral (antibody) and cell-mediated immune responses to provide protection against these diseases.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Vaxelis vaccine

What is Vaxelis vaccine?

Vaxelis vaccine is a Combination vaccine drug developed by Sanofi, indicated for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilus influenzae type b, meningococcal disease (serogroup C), measles, mumps, rubella, and varicella in infants and children.

How does Vaxelis vaccine work?

Vaxelis is a combination vaccine that stimulates the immune system to produce antibodies and cellular immunity against multiple infectious diseases simultaneously.

What is Vaxelis vaccine used for?

Vaxelis vaccine is indicated for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilus influenzae type b, meningococcal disease (serogroup C), measles, mumps, rubella, and varicella in infants and children.

Who makes Vaxelis vaccine?

Vaxelis vaccine is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

Is Vaxelis vaccine also known as anything else?

Vaxelis vaccine is also known as Vaxelis™, Vaxelis®.

What drug class is Vaxelis vaccine in?

Vaxelis vaccine belongs to the Combination vaccine class. See all Combination vaccine drugs at /class/combination-vaccine.

What development phase is Vaxelis vaccine in?

Vaxelis vaccine is in Phase 3.

What are the side effects of Vaxelis vaccine?

Common side effects of Vaxelis vaccine include Injection site reactions (pain, redness, swelling), Fever, Irritability, Drowsiness, Loss of appetite.

Related